First People's Hospital

Risperidone is a small-molecule antipsychotic approved globally for schizophrenia treatment. This program, designated 2018YFC1314300 and sponsored by The First People's Hospital of Lianyungang, represents a Phase 1 clinical investigation of risperidone administered via intramuscular injection (brand: APO-RISPERIDONE). Risperidone is a dopamine and serotonin antagonist belonging to the nervous system therapeutic class (N05). The drug has been approved in multiple major markets including the United States, European Union, Japan, and Australia, with numerous generic manufacturers authorized across these regions. The current Phase 1 trial (NCT03790085) is actively investigating the compound, with the latest documented milestone dated 31 December 2018. As a well-established antipsychotic with decades of clinical use, this program likely focuses on formulation optimization, safety profiling, or regional regulatory compliance rather than novel mechanism discovery. The competitive landscape includes multiple approved atypical antipsychotics including aripiprazole (ABILIFY), olanzapine (APO-OLANZAPINE ODT), paliperidone (INVEGA), and lurasidone (APO-LURASIDONE). Risperidone's intramuscular formulation addresses treatment adherence challenges in schizophrenia management, a significant clinical concern in this patient population.

Schizophrenia affects approximately 20 million people globally and represents a major public health burden with substantial morbidity, mortality, and economic costs. Treatment adherence remains a critical unmet need; approximately 40–50% of patients discontinue antipsychotic therapy within the first year due to side effects, cognitive burden, or lack of insight into illness. Long-acting intramuscular formulations of antipsychotics address this challenge by extending dosing intervals from daily to weekly or monthly administration, significantly improving medication adherence and reducing relapse rates.

Risperidone's intramuscular formulation competes within a mature but clinically important market segment. The competitive landscape includes established long-acting injectables such as paliperidone palmitate (INVEGA), aripiprazole monohydrate, and olanzapine pamoate. Despite market maturity, clinical need remains substantial: poor adherence drives approximately 40% of psychiatric hospitalizations in schizophrenia. Regional regulatory pathways, manufacturing optimization, and formulation improvements continue to generate clinical and commercial value.

This Phase 1 program, conducted in China, likely supports regional regulatory approval, manufacturing scale-up, or bioequivalence demonstration for generic or biosimilar risperidone formulations. The Chinese market represents a significant opportunity given the high prevalence of schizophrenia and growing mental health service infrastructure. Successful completion of this trial may enable market entry or expanded distribution in China and other Asian markets where risperidone adoption remains below saturation.

Drug Class: Atypical antipsychotic (second-generation antipsychotic)

Mechanism of Action: Dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist. This dual antagonism reduces positive symptoms of schizophrenia (hallucinations, delusions) while maintaining lower risk of extrapyramidal side effects compared to first-generation antipsychotics.

Modality: Small-molecule organic compound

Route of Administration: Intramuscular injection

Molecular Target: Not yet disclosed in available documentation

Therapeutic Class: Nervous system agents (ATC N05)

Related Therapies: Other atypical antipsychotics including aripiprazole, olanzapine, paliperidone, quetiapine, lurasidone, and iloperidone. Risperidone was among the first atypical antipsychotics approved (oral formulation approved in the United States in 1993; long-acting injectable formulations approved subsequently).

First Approval: Oral risperidone approved in the United States in 1993 (NDA020272, NDA020588). Intramuscular formulations approved in multiple markets thereafter. Australian approval documented from 1996 onwards across multiple sponsors.

Patent Status: Not yet disclosed. Risperidone's original patents have expired; current formulations and manufacturing processes may be protected by secondary patents or regulatory exclusivity.

United States (FDA): Risperidone approved via NDA020272 and NDA020588 (original approvals). Over 50 ANDA applications for generic risperidone approved, including formulations from Actavis Labs FL Inc, Ajanta Pharma Ltd, Amneal, Apotex Inc, Aurobindo Pharma Ltd, Dr Reddy's Labs Ltd, Janssen Pharms, Sandoz, Teva, and others. Long-acting injectable formulations approved under separate NDAs (NDA210655, NDA212849, NDA213586, NDA214835).

European Union (EMA): Risperidone approved across multiple member states. Long-acting injectable formulation (OKEDI) authorized under EMEA/H/C/005406 by Laboratorios Farmacéuticos Rovi, S.A., with authorization date 11 October 2025.

Japan (PMDA): Risperidone approved; approval date documented as February 2016.

Australia (TGA): Risperidone approved and listed on ARTG with multiple PBS codes (11869Q, 11874Y, 11877D, 11879F, 11881H, 11882J, 14686Y, 14688C, 3169T, 3170W). Multiple sponsors authorized including Alphapharm Pty Ltd, Apotex Pty Ltd, Arrow Pharma Pty Ltd, Generic Health Pty Ltd, and Janssen-Cilag Pty Ltd. First listed dates range from 1 November 1996 to 1 December 2008.

China (NMPA): Risperidone in clinical trials; NCT03510325 documents ongoing clinical investigation in China. The Phase 1 program (2018YFC1314300) represents regulatory pathway development in this market.

Expected Loss of Exclusivity (LOE): Not yet disclosed. Original risperidone patents have expired globally; current formulations may benefit from secondary patent protection or regulatory exclusivity periods.

• Strategic Rationale: This Phase 1 program, sponsored by a Chinese hospital and designated with a Chinese research code (2018YFC1314300), likely supports regulatory approval or bioequivalence demonstration for risperidone intramuscular formulation in China. Given risperidone's global approval history and mature development status, this trial probably focuses on regional manufacturing, formulation optimization, or pharmacokinetic characterization rather than novel safety or efficacy discovery.
• Market Opportunity: China represents a significant untapped market for long-acting antipsychotic injectables. Mental health service infrastructure is expanding rapidly, and schizophrenia prevalence is substantial. Successful regulatory approval could enable market entry for risperidone intramuscular formulation in China and potentially other Asian markets, capturing market share before newer agents establish dominance.
• Competitive Implications: Risperidone's intramuscular formulation faces established competition from paliperidone (INVEGA Sustenna) and aripiprazole monohydrate in developed markets. However, in China and emerging markets, generic risperidone's lower cost and established safety profile provide competitive advantage. This program may enable risperidone to capture price-sensitive segments before premium agents achieve market penetration.
• Clinical Catalysts: Expected milestones include Phase 1 completion, regulatory submission to NMPA (China), and potential approval decision. Timeline for these events is not yet disclosed. Successful completion may trigger Phase 2/3 trials or direct regulatory approval depending on Chinese regulatory pathway requirements.
• Risk Factors: Risperidone's mature development status and extensive generic competition limit commercial upside. Regulatory approval in China may be delayed by evolving NMPA requirements or manufacturing compliance issues. Competition from established long-acting injectables and newer agents with improved metabolic profiles poses ongoing competitive risk.